Skip Navigation

British Journal of Anaesthesia 2007 99(2):151-154; doi:10.1093/bja/aem205
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sear, J. W.
Right arrow Articles by Howard-Alpe, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sear, J. W.
Right arrow Articles by Howard-Alpe, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Preoperative plasma BNP concentrations: do they improve our care of high-risk non-cardiac surgical patients?

The first 150 words of the full text of this article appear below.

There is presently much interest in the preoperative identification of high-risk patients undergoing major surgery—with the aim of adopting management strategies which may reduce postoperative morbidity and mortality.1 In the non-cardiac surgical patient, data for the UK suggest that there may be up to 8000 cardiovascular deaths per year for 5 million surgical procedures performed, with an incidence of 10 times that with regard to morbidity (myocardial infarction, congestive cardiac failure, malignant arrhythmias, and cardiac arrest).2 The major pathological disorder responsible for these adverse outcomes is ischaemic heart disease, either overt or covert, secondary to atherosclerosis. We, and others, have recently reviewed the role of biomarkers in the identification of at-risk cardiac patients.3 4

For a test to be useful as a biomarker, it should to be able to differentiate between the ‘healthy’ and the ‘compromised’ patient. In epidemiological terms, it needs to have a high sensitivity (probability that the biomarker . . . [Full Text of this Article]

Addendum

J. W. Sear* and G. Howard-Alpe

Oxford, UK

* E-mail: john.sear@nda.ox.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
A. Oscarsson, M. Fredrikson, M. Sorliden, S. Anskar, and C. Eintrei
N-terminal fragment of pro-B-type natriuretic peptide is a predictor of cardiac events in high-risk patients undergoing acute hip fracture surgery
Br. J. Anaesth., August 1, 2009; 103(2): 206 - 212.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
E. Mahla, M. Vicenzi, W. Toller, B. H. Cuthbertson, and (on behalf of the authors)
B-type natriuretic peptide in high-risk major surgery patients
Br. J. Anaesth., November 1, 2007; 99(5): 746 - 747.
[Full Text] [PDF]